Felix Bergmann, Michael Wölfl‐Duchek, Anselm Jorda, Valentin al Jalali, Amelie Leutzendorff, Maria Sanz-Codina, Daniela Gompelmann, Karin Trimmel, Maria Weber, Sabine Eberl, Wisse van Os, Iris K. Minichmayr, Birgit Reiter, Thomas Stimpfl, Marco Idzko, Markus Zeitlinger,
Abstract Background Invasive aspergillosis is a severe fungal infection that affects multiple organ systems including the CNS and the lungs. Isavuconazole, a novel triazole antifungal agent, has demonstrated promising activity against Aspergillus spp. However, data on the penetration of isavuconazole into the CNS and ELF and intracellular accumulation remain limited. Materials and methods We conducted a prospective single-centre pharmacokinetic (PK) study in 12 healthy volunteers. Subjects received ...
Tópico(s): Helminth infection and control
2024 - Oxford University Press | Journal of Antimicrobial Chemotherapy
... the Burgtheater in the last thirtyyears or so, Birgit Minichmayr's much-praised performance as Grillparzer's Medea, ...
2006 - Modern Humanities Research Association | Austrian Studies
... the Burgtheater in the last thirtyyears or so, Birgit Minichmayr's much-praised performance as Grillparzer's Medea, ...
2006 - Modern Humanities Research Association | Austrian Studies
Sebastian G. Wicha, Anne‐Grete Märtson, Elisabet I. Nielsen, Birgit C. P. Koch, Lena E. Friberg, Jan‐Willem C. Alffenaar, Iris K. Minichmayr,
Therapeutic drug monitoring (TDM) and model‐informed precision dosing (MIPD) have evolved as important tools to inform rational dosing of antibiotics in individual patients with infections. In particular, critically ill patients display altered, highly variable pharmacokinetics and often suffer from infections caused by less susceptible bacteria. Consequently, TDM has been used to individualize dosing in this patient group for many years. More recently, there has been increasing research on the use ...
Tópico(s): Bacterial Identification and Susceptibility Testing
2021 - Wiley | Clinical Pharmacology & Therapeutics
Amelie Blaschke, Valentin al Jalali, Martin Bauer, Iris K. Minichmayr, Birgit Reiter, Michael Wölfl ‐ Duchek, Alina Nussbaumer‐Pröll, Maria Weber, Sabine Eberl, Marie Spies, Maysa Sarhan, Johannes Geilen, A. Walther, Daniel Drai, Markus Zeitlinger,
Abstract Aims Clomipramine (CLOMI) has shown effectiveness in treating premature ejaculation but is linked to erectile dysfunction and reduced libido. Yohimbine (YOH), by contrast, is effective in treating erectile dysfunction and may improve libido. Combining CLOMI and YOH could potentially leverage the benefits of both drugs. This study aimed to investigate the interactions between these drugs and to evaluate their safety profile. Methods A prospective, open‐labelled, single‐centre, pharmacokinetic ( ...
Tópico(s): Pharmacology and Obesity Treatment
2024 - Wiley | British Journal of Clinical Pharmacology
Juergen Grafeneder, Wisse van Os, Iris K. Minichmayr, Katarina D. Kovacevic, Birgit Reiter, M. D. Saemann, Veronika Machold-Fabrizii, Amro Ahmed, Paul Spechtl, Haris Omić, Raute Sunder‐Plaßmann, Bernd Jilma, Christian Schoergenhofer, Farsad Eskandary,
IntroductionHemodialysis patients (HDPs) exhibit extensive cardiovascular risk. The widely prescribed anti-platelet agent clopidogrel is metabolically activated by cytochrome enzymes, which may be impaired by uremia and chronic low-grade inflammation, typically present in HDPs. We conducted a prospective multicenter study to investigate the pharmacokinetics and pharmacodynamics of clopidogrel in HDPs and healthy volunteers (HVs).MethodsWe enrolled HDPs receiving long-term clopidogrel (75 mg) and pantoprazole ...
Tópico(s): Pharmacology and Obesity Treatment
2024 - Elsevier BV | Kidney International Reports